V etoy stat'e my provodim obsuzhdenie 9 rekomendatsiy, kotorye razrabotany standartnym metodom sochetaniya dokazatel'nykh issledovaniy i konsensusa ekspertov. V svyazi s bol'shim spektrom klinicheskikh fenotipov deponirovaniya kristallov pirofosfata kal'tsiya (PFK) terapiya bolezni predstavlyaet slozhnuyu zadachu, tem bolee chto, v otlichie ot podagry, v nastoyashchee vremya net spetsificheskoy terapii, sposobstvuyushchey ischeznoveniyu PFK. Poetomu lechenie sfokusirovano na kontrole klinicheskikh simptomov kak ostrogo, tak i khronicheskogo artrita. Ispol'zuyutsya podkhody, analogichnye takovym pri terapii ostrogo podagricheskogo artrita, kontrole boli i simptomov pri osteoartroze (OA).

Objective. To study the prevalence and degree of risk factors for cardiovascular diseases (CVD) and the transformation of the clinical picture of gout in the past 20 years.
Material and methods. The case histories of 305 male gouty patients (mean age 45.6+11.7years) treated at the Rheumatology Department, S.P. Botkin Faculty Therapy Clinic, S.M. Kirov Military Medical in 1990 to 1994 and 2005 to 2009 were retrospectively analyzed. The pattern and prevalence of CVD and the presence of risk factors were studied in patients with gout.
Results. The currently ill patients were found to have high body mass index, high arterial hypertension, more pronounced metabolic changes and carbohydrate metabolic disturbances, and a high atherogenic blood lipid profile, which were correlated with elevated uric acid levels. There was also a high frequency of chronic CVD.
Conclusion. The found changes point to the transformation of the disease over a number of years and the steady increase in the degrees of a cardiovascular risk in gouty patients with metabolic disturbances.

Objective. To estimate patient adherence to treatment with antiosteoporotic drugs within the first year after experienced low-trauma osteoporotic fractures (LOF).
Material and methods. The data of a questionnaire survey were analyzed in 172 women aged 50 years or older (mean age 66+8 years) who had sustained fractures at different sites after a fall from standing height, were analyzed. Therapy and its compliance were assessed 12 months after LOF. Results and discussion. Among the 172 respondents, 55% received therapy, including 73% took only calcium preparations and vitamin D; 8% calcitonin; 14% bisphosphonates; 5% strontium ranelate. At the same time, 45% of those asked were given no antiosteoporotic drugs within the first year of life after fracture. Only 42%> continued to receive treatment following 12 months; 18% interrupted it within the first 4 months after fracture. Conclusion. In real clinical practice, osteoporosis was not treated in the majority of patients within the first year after LOF. One of the major reasons why it is not treated is the high cost of pathogenetic drugs. This reason can be successfully eliminated using generic drugs.

The paper presents the results of a trial of the efficacy and safety of the nonsteroidal anti-inflammatory drug Amelotex® (international nonproprietary name meloxicam) in patients with pyrophosphate arthropathy (PA). One-month Amelotex® therapy is shown to have a good clinical effect in patients with different forms of PA, to improve quality-of-life indices, and to show good tolerability.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed by physicians for various ab-normalities every day. Despite their high antiinflammatory and analgesic effects, the safety issues of the drugs are, however, of most importance. Meloxicam occupies a special place among NSAIDs, complies with all requirements for this group of medications, and shows a good toler-ability, as evidenced by numerous clinical trials.

Meticulous attention is paid to the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs), the so-called selective cyclooxy-genase 2 (COX-2) inhibitors in particular. The author considers precisely this matter in case of Russia's recent NSAID etoricoxib that has been tested along with other most studied medications from this group, by applying one of the latest meta-analyses. The EULAR recommendations to use NSAIDs are given.

Glucosamine sulfate, or hydrochloride, and chondroitin sulfate are natural components of cartilaginous intercellular substance. In osteoarthrosis (OA), they exert a pronounced symptom-modifying effect and, when used long, they can also inhibit the X-ray progression of OA. The combination drugs that comprise glucosamine and chondroitin have some advantage over each component. These agents include teraflex. The efficacy of these pharmacological agents seems to be associated with their anti-inflammatory properties rather than with the stimulated synthesis of cartilaginous matrix.

The paper considers the major effects of cyclosporin A (CsA) in rheumatic diseases (RD). CsA is noted to be effective for a number of RDs and all types of rheumatoid arthritis (RA), including in early RA in adults and juvenile RA; uveitis associated with Behcet's disease (BD) (as the drug of choice); in combination with other disease-modifying drugs; in RD with concomitant viral hepatitis C. The diagnostic criteria for (BD) and the efficacy of CsA for this disease are given according to different authors.

The paper analyzes the data obtained by Pharmexpert on the sales of nonsteroidal anti-inflammatory drugs in the Russian Federation. Ibuprofen, ketorolac, diclofenac, and nimesulide are sales leaders. Possible reasons for the popularity of a number of medications and whether it is expedient to use intramuscular formulations are considered. The WHO data on indi-cations for and contraindications to the use of injectable dosage form are given.